» Articles » PMID: 3494191

Epidermal Growth Factor Receptor Gene-amplified MDA-468 Breast Cancer Cell Line and Its Nonamplified Variants

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 1987 Jan 1
PMID 3494191
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

We have recently reported (J. Filmus, M. N. Pollak, R. Cailleau, and R. N. Buick, Biochem. Biophys. Res. Commun. 128:898-905, 1985) that MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited in vitro pharmacological doses of EGF. We have derived several MDA-468 clonal variants which are resistant to EGF-induced growth inhibition. These clones had a number of EGF receptors, similar to normal human fibroblasts, and had lost the EGF receptor gene amplification. Karyotype analysis showed that MDA-468 cells had an abnormally banded region (ABR) in chromosome 7p which was not present in the variants. It was shown by in situ hybridization that the amplified EGF receptor sequences were located in that chromosome, 7pABR. Five of the six variants studied were able to generate tumors in nude mice, but their growth rate was significantly lower than that of tumors derived from the parental cell line. The variant that was unable to produce tumors was found to be uniquely dependent on EGF for growth in soft agar.

Citing Articles

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer 
with Epidermal Growth Factor Receptor Gene Mutation].

Huang J, Wang H Zhongguo Fei Ai Za Zhi. 2022; 25(3):183-192.

PMID: 35340161 PMC: 8976207. DOI: 10.3779/j.issn.1009-3419.2022.101.05.


Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts.

Kuiken H, Dhakal S, Selfors L, Friend C, Zhang T, Callari M Oncogene. 2021; 41(1):112-124.

PMID: 34703030 PMC: 8727509. DOI: 10.1038/s41388-021-02075-y.


Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.

Maisel S, Broka D, Atwell B, Bunch T, Kupp R, Singh S J Transl Med. 2019; 17(1):201.

PMID: 31215437 PMC: 6582486. DOI: 10.1186/s12967-019-1939-7.


Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.

Miller-Kleinhenz J, Bozeman E, Yang L Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015; 7(6):797-816.

PMID: 25966677 PMC: 4604004. DOI: 10.1002/wnan.1343.


Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.

Balanis N, Wendt M, Schiemann B, Wang Z, Schiemann W, Carlin C J Biol Chem. 2013; 288(25):17954-67.

PMID: 23653350 PMC: 3689941. DOI: 10.1074/jbc.M113.475277.


References
1.
Biedler J, Riehm H . Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 1970; 30(4):1174-84. View

2.
Kudlow J, Cheung C, Bjorge J . Epidermal growth factor stimulates the synthesis of its own receptor in a human breast cancer cell line. J Biol Chem. 1986; 261(9):4134-8. View

3.
Rigby P, Dieckmann M, Rhodes C, Berg P . Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol. 1977; 113(1):237-51. DOI: 10.1016/0022-2836(77)90052-3. View

4.
Pathak S, Siciliano M, CAILLEAU R, Wiseman C, Hsu T . A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line. J Natl Cancer Inst. 1979; 62(2):263-71. View

5.
Carpenter G, Cohen S . Epidermal growth factor. Annu Rev Biochem. 1979; 48:193-216. DOI: 10.1146/annurev.bi.48.070179.001205. View